Aktuelle smitsomme sygdomme
Søgeord (mycoplasma) valgt.
27 emner vises.
Daniel Todkill, Theresa Lamagni, Richard Pebody, Mary Ramsay, Daisy Woolham, Alicia Demirjian, Antoine Salzmann, Meera Chand, Helen E Hughes, Christopher Bennett, Russell Hope, Conall H Watson, Colin S Brown and Alex J Elliot
Eurosurveillance latest updates, 9.08.2024
Tilføjet 9.08.2024
Since November 2023, the absolute number of attendances at emergency departments for pneumonia among children aged 5–14 years in England have been above expected levels for the time of year. This increased signal peaked during March 2024 but then persisted into early summer 2024 despite decreases in prevalence of seasonal respiratory pathogens. Record linkage between emergency department and laboratory databases points to this unusual activity being driven largely by Mycoplasma pneumoniae.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 22.02.2024
Tilføjet 22.02.2024
This report describes an increase in Mycoplasma pneumoniae, a common cause of respiratory illness, beginning in fall 2023.
Læs mereIrith De Baetselier, Hilde Smet, Kaat Kehoe, Imelda Loosen, Marijke Reynders, Iqbal Mansoor, Lorenzo Filippin, Mathieu Cauchie, Ellen Van Even, Nadia Makki, Gilberte Schiettekatte, Wouter Vandewal, Bart Glibert, Veerle Matheeussen, Yolien Van der Beken, Reinoud Cartuyvels, Sophia Steyaert, Ann Lemmens, Maria-Grazia Garrino, Henry Paridaens, Elena Lazarova, Bénédicte Lissoir, Marine Deffontaine, Amélie Heinrichs, Veroniek Saegeman, Elizaveta Padalko, Amaryl Lecompte, Wim Vanden Berghe, Chris Kenyon and Dorien Van den Bossche
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
BackgroundAntimicrobial resistance (AMR) of Mycoplasma genitalium (MG) is a growing concern worldwide and surveillance is needed. In Belgium, samples are sent to the National Reference Centre of Sexually Transmitted Infections (NRC-STI) on a voluntary basis and representative or robust national AMR data are lacking. AimWe aimed to estimate the occurrence of resistant MG in Belgium. MethodsBetween July and November 2022, frozen remnants of MG-positive samples from 21 Belgian laboratories were analysed at the NRC-STI. Macrolide and fluoroquinolone resistance-associated mutations (RAMs) were assessed using Sanger sequencing of the 23SrRNA and parC gene. Differences in resistance patterns were correlated with surveillance methodology, socio-demographic and behavioural variables via Fisher’s exact test and logistic regression analysis. ResultsOf the 244 MG-positive samples received, 232 could be sequenced for macrolide and fluoroquinolone RAMs. Over half of the sequenced samples (55.2%) were resistant to macrolides. All sequenced samples from men who have sex with men (MSM) (24/24) were macrolide-resistant. Fluoroquinolone RAMs were found in 25.9% of the samples and occurrence did not differ between socio-demographic and sexual behaviour characteristics. ConclusionAlthough limited in sample size, our data suggest no additional benefit of testing MG retrieved from MSM for macrolide resistance in Belgium, when making treatment decisions. The lower occurrence of macrolide resistance in other population groups, combined with emergence of fluoroquinolone RAMs support macrolide-resistance testing in these groups. Continued surveillance of resistance in MG in different population groups will be crucial to confirm our findings and to guide national testing and treatment strategies.
Læs mereDita C Bolluyt, Sjoerd M Euser, Dennis Souverein, Annemarie MC van Rossum, Jayant Kalpoe, Mireille van Westreenen, Marco Goeijenbier, Dominic Snijders, Dirk Eggink, Femke Jongenotter, Steven FL van Lelyveld and Marlies A van Houten
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
Mycoplasma pneumoniae is an important cause of pneumonia and extra-pulmonary manifestations. We observed a rise in admissions due to M. pneumoniae infections starting October 2023 in a regional hospital in the Netherlands and an increased incidence in national surveillance data. The incidence in the Netherlands has not been that high since 2011. The patients had a lower median age compared with 2019 and 2020 (28 vs 40 years). M. pneumoniae should be considered in patients with respiratory symptoms, especially children.
Læs mereCheng Gong, Fang Huang, Luodan Suo, Xuejiao Guan, Lu Kang, Hui Xie, Geng Hu, Peng Yang and Quanyi Wang
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
In 2023, through an ongoing respiratory pathogen surveillance system, we observed from mid-September onwards, an increase of respiratory illness among children aged ≤ 15 years presenting at hospital outpatient clinics in Beijing, China. Data indicated that illness was caused by multiple pathogens, predominantly Mycoplasma pneumoniae. Seasonality, periodicity and high prevalence of resistance to macrolide (30 of 30 strains sequenced with the A2063G mutation) were important characteristics of the M. pneumoniae epidemic, which resulted in a rise in consultations at specialised paediatric hospitals.
Læs mereAnne Christine Nordholm, Bolette Søborg, Pikka Jokelainen, Karina Lauenborg Møller, Lotte Flink Sørensen, Tyra Grove Krause, Søren Anker Uldum and Hanne-Dorthe Emborg
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
We report a surge of patients, especially children and adolescents, with respiratory disease caused by Mycoplasma pneumoniae in Denmark since October 2023. While the surge has reached an epidemic level, no impact on hospital capacity has been observed; only 14% (446/3,195) of cases, primarily adults, required hospitalisation. Macrolide resistance was detected in less than 2% of samples tested. Timely monitoring of hospitalisations linked to M. pneumoniae infections has been established to inform the healthcare system, decisionmakers and the public.
Læs mereECDC
ECDC Communicable Disease Threats Report, 8.12.2023
Tilføjet 8.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 3-9 December 2023 and includes updates on respiratory virus epidemiology in the EU/EEA, SARS-CoV-2 variant classification, measles, mpox, Mycoplasma pneumoniae, West Nile virus, and MERS-CoV.
Læs mereECDC
ECDC COVID-19 updates, 8.12.2023
Tilføjet 8.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 3-9 December 2023 and includes updates on respiratory virus epidemiology in the EU/EEA, SARS-CoV-2 variant classification, measles, mpox, Mycoplasma pneumoniae, West Nile virus, and MERS-CoV.
Læs mereECDC
ECDC Communicable Disease Threats Report, 2.12.2023
Tilføjet 2.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19 - 25 November 2023 and includes updates on human infection with influenza A(H1N2)v, influenza A(H5N1), an overview of respiratory virus epidemiology in the EU/EEA, respiratory infections due to Mycoplasma pneumoniae in the EU/EEA, HIV/AIDS surveillance 2023 (2022 data), West Nile virus, SARS-CoV-2 variant classification, and poliomyelitis.
Læs mereECDC
ECDC COVID-19 updates, 1.12.2023
Tilføjet 1.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19 - 25 November 2023 and includes updates on human infection with influenza A(H1N2)v, influenza A(H5N1), an overview of respiratory virus epidemiology in the EU/EEA, respiratory infections due to Mycoplasma pneumoniae in the EU/EEA, HIV/AIDS surveillance 2023 (2022 data), West Nile virus, SARS-CoV-2 variant classification, and poliomyelitis.
Læs mereStatens Serum Institut, 29.11.2023
Tilføjet 29.11.2023
Der har siden sommeren været en stigning i antallet af luftvejsinfektioner med Mycoplasma pneumoniae, og forekomsten har nu nået et epidemisk niveau med væsentlig flere tilfælde end normalt.
Læs mereProMED, 3.05.2023
Tilføjet 3.05.2023
Porcine Circovirus -- United StatesThe latest Swine Disease Reporting System report has some people scratching their heads. For the 1st time in recent memory, porcine circovirus type 2 (PCV2) jumped into the top 10 most-diagnosed diseases list at the Iowa State University Veterinary Diagnostic Lab. At No. 9, it surpassed porcine epidemic diarrhea virus and came in just behind _Mycoplasma hyopneumoniae_.Porcine-circovirus-associated disease (PCVAD) can be caused by any PCV2 strain. When PCVAD 1st showed up in the US in
Læs mereProMED, 11.03.2023
Tilføjet 11.03.2023
Other Animal Disease -- United StatesThe Wyoming Game and Fish Department, in collaboration with the Wyoming State Veterinary Laboratory, is investigating a rare disease outbreak in pronghorn in western Wyoming.Game and Fish is estimating that approximately 200 animals have died since mid-February [2023], centered around the southern end of the Mesa south of Pinedale. Preliminary lab results identify _Mycoplasma bovis_ as the pathogen causing the mortalities._M. bovis_ should not be confused with _Mycobacterium bovis_
Læs mereProMED, 1.02.2023
Tilføjet 1.02.2023
Other Animal Disease -- New ZealandA review of the cluster of farms infected with cattle disease _Mycoplasma bovis_ in Mid-Canterbury has ruled it could be spreading via airborne transmission. The Ministry for Primary Industries (MPI) has released the findings of an independent review into _M. bovis_ infection in Wakanui near Ashburton. MPI, Dairy NZ, and Beef & Lamb New Zealand ordered the review in mid-2022 after it became apparent infection was circulating in a small geographical area despite the use of disease control
Læs mereProMED, 28.01.2023
Tilføjet 28.01.2023
Toxoplasmosis -- United StatesFisk EA, Cassirer EF, Huggler KS, et al. Abortion and neonatal mortality due to _Toxoplasma gondii_ in bighorn sheep (_Ovis canadensis_). J. Wildl. Dis. 2023; . Epub ahead of print.Bighorn sheep have experienced disease driven impact for several years, and thus the health dimension is a very important aspect of their conservation. Many mortality episodes have been caused by bighorn sheep pneumonia, which is mainly caused by _Mycoplasma ovipneumoniae_ (Movi), an exotic disease agent for
Læs mereProMED, 27.01.2023
Tilføjet 27.01.2023
Bovine Pleuropneumonia -- UgandaBovine pleuropneumonia kills 300 cattle in Agago. The disease has been confirmed in 3 sub-counties; Paimol, Laimuto, and Omiya Pachwa, where the majority of farmers were advised to keep their animals in communal kraals [enclosures for cattle or other livestock], to protect them against Karamojong cattle rustlers.--Communicated by:ProMED Rapporteur Mahmoud Orabi['Contagious bovine pleuropneumonia (CBPP) is a disease of cattle and water buffalo caused by _Mycoplasma mycoides_ subsp.
Læs mereProMED, 24.10.2022
Tilføjet 24.10.2022
ProMED, 10.10.2022
Tilføjet 10.10.2022
ProMED, 27.09.2022
Tilføjet 28.09.2022
Medscape Infectious Diseases, 12.08.2022
Tilføjet 12.08.2022
Macrolide-resistant mycoplasma genitalium's favorite hiding place turns out to be the vaginal tract. Now what?
Læs mereProMED, 22.06.2022
Tilføjet 23.06.2022
Patrick M Meyer Sauteur, Michael L Beeton, Søren A Uldum, Nathalie Bossuyt, Melissa Vermeulen, Katherine Loens, Sabine Pereyre, Cécile Bébéar, Darja Keše, Jessica Day, Baharak Afshar, Victoria J Chalker, Gilbert Greub, Ran Nir-Paz, Roger Dumke and ESGMAC–MyCOVID Study Team
Eurosurveillance latest updates, 12.05.2022
Tilføjet 13.05.2022
Background
Mycoplasma pneumoniae respiratory infections are transmitted by aerosol and droplets in close contact.
Aim
We investigated global M. pneumoniae incidence after implementation of non-pharmaceutical interventions (NPIs) against COVID-19 in March 2020.
Methods
We surveyed M. pneumoniae detections from laboratories and surveillance systems (national or regional) across the world from 1 April 2020 to 31 March 2021 and compared them with cases from corresponding months between 2017 and 2020. Macrolide-resistant M. pneumoniae (MRMp) data were collected from 1 April 2017 to 31 March 2021.
Results
Thirty-seven sites from 21 countries in Europe, Asia, America and Oceania submitted valid datasets (631,104 tests). Among the 30,617 M. pneumoniae detections, 62.39% were based on direct test methods (predominantly PCR), 34.24% on a combination of PCR and serology (no distinction between methods) and 3.37% on serology alone (only IgM considered). In all countries, M. pneumoniae incidence by direct test methods declined significantly after implementation of NPIs with a mean of 1.69% (SD ± 3.30) compared with 8.61% (SD ± 10.62) in previous years (p < 0.01). Detection rates decreased with direct but not with indirect test methods (serology) (–93.51% vs + 18.08%; p < 0.01). Direct detections remained low worldwide throughout April 2020 to March 2021 despite widely differing lockdown or school closure periods. Seven sites (Europe, Asia and America) reported MRMp detections in one of 22 investigated cases in April 2020 to March 2021 and 176 of 762 (23.10%) in previous years (p = 0.04).
Conclusions
This comprehensive collection of M. pneumoniae detections worldwide shows correlation between COVID-19 NPIs and significantly reduced detection numbers.
Læs mereIrena Klavs, Maja Milavec, Lina Berlot, Tanja Kustec, Marta Grgič-Vitek, Darja Lavtar, Metka Zaletel, Andrej Golle, Darja Duh and Tjaša Žohar Čretnik
Eurosurveillance latest updates, 7.04.2022
Tilføjet 8.04.2022
Background
To inform prevention and control of sexually transmitted infections (STIs), we need reliable prevalence estimates.
Aim
One objective of the Slovenian National Survey of Sexual Lifestyles, Attitudes and Health was to estimate the prevalence of STIs with Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Trichomonas vaginalis.
Methods
Data were collected between October 2016 and July 2017 in a probability sample of the general population aged 18–49 years. Computer-assisted face-to-face interviewing and self-completion of questionnaires were used. Respondents were invited to provide urine samples to be tested for STIs.
Results
Of 1,929 survey participants, 1,087 individuals provided urine samples which were tested confidentially for C. trachomatis and a subset (n = 1,023) were tested anonymously for the other STIs. The prevalence of C. trachomatis was 0.5% (95% confidence interval (CI): 0.1–1.8) in men and 1.7% (95% CI: 0.9–3.2) in women. Age-specific prevalence was the highest among individuals aged 18–24 years, 2.8% (95% CI: 0.7–10.6) in men and 4.7% (95% CI: 1.7–12.3) in women. N. gonorrhoea was not detected. Prevalence of M. genitalium was 0.5% (95% CI: 0.1–2.2) in men and 0.3% (95% CI: 0.1–1.1) in women; the highest prevalence was among men aged 25–34 years (1.1%; 95% CI: 0.2–7.5) and women aged 35–49 years (0.5%; 95% CI: 0.1–2.0). T. vaginalis was detected in the sample from one woman (0.2%; 95% CI: 0.1–1.2).
Conclusion
The substantial prevalence of C. trachomatis among young adults suggests gaps in testing, diagnosis and treatment.
Læs mereHendrik Streeck, Klaus Jansen, Trevor A Crowell, Allahna Esber, Heiko K Jessen, Christiane Cordes, Stefan Scholten, Stephan Schneeweiss, Norbert Brockmeyer, Christoph D Spinner, Markus Bickel, Stefan Esser, Jukka Hartikainen, Albrecht Stoehr, Clara Lehmann, Ulrich Marcus, Jörg Janne Vehreschild, Alexandra Knorr, Anna-Lena Brillen, Carsten Tiemann, Merlin L Robb and Nelson L Michael
Eurosurveillance latest updates, 7.04.2022
Tilføjet 8.04.2022
Introduction
Despite increased use of pre-exposure prophylaxis (PrEP) in Germany, HIV infection rates are not declining and little is known about how this prevention method affects the prevalence of sexually transmitted infections (STI) among men who have sex with men (MSM).
Aim
We studied, in a large multicentre cohort, STI point prevalence, co-infection rates, anatomical location and influence of PrEP.
Methods
The BRAHMS study was a prospective cohort study conducted at 10 sites in seven major German cities that enrolled MSM reporting increased sexual risk behaviour. At screening visits, MSM were tested for Mycoplasma genitalium (MG), Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Treponema pallidum (TP), and given a behavioural questionnaire. With binomial regression, we estimated prevalence ratios (PR) and 95% confidence intervals (CI) for the association of PrEP and STI.
Results
We screened 1,043 MSM in 2018 and 2019, with 53.0% currently using PrEP. At screening, 370 participants (35.5%) had an STI. The most common pathogen was MG in 198 (19.0%) participants, followed by CT (n = 133; 12.8%), NG (n = 105; 10.1%) and TP (n = 37; 3.5%). Among the 370 participants with at least one STI, 14.6% (n = 54) reported STI-related symptoms. Infection prevalence was highest at anorectal site (13.4% MG, 6.5% NG, 10.2% CT). PrEP use was not statistically significant in adjusted models for STI (PR: 1.10; 95% CI: 0.91–1.32), NG/CT, only NG or only CT.
Conclusions
Prevalence of asymptomatic STI was high, and PrEP use did not influence STI prevalence in MSM eligible for PrEP according to national guidelines.
Læs mereStatens Serum Institut, 9.03.2016
Tilføjet 11.03.2021
Siden efteråret 2015 har der været en landsdækkende Mycoplasma pneumoniae-epidemi, EPI-NYT 49/15.
Læs mereStatens Serum Institut, 6.01.2016
Tilføjet 11.03.2021
Resistens med behandlingssvigt efter moxifloxacin behandling af M. genitalium ses i stigende grad, særligt hos patienter, som har erhvervet infektionen i Sydøstasien eller Australien.
Læs mereStatens Serum Institut, 4.11.2015
Tilføjet 11.03.2021
I den seneste måned er der påvist mere end dobbelt så mange infektioner med Mycoplasma pneumoniae (populært kaldet "kold lungebetændelse") sammenlignet med samme periode sidste år.
Læs mere